Fairvalue-Calculator Fairvalue-Calculator
EN DE

Voxel S.A (VOX) Fair Value & Analysis

Healthcare · PL · Market cap 1.2B PLN

Price115.60 PLN
Fair Value201.85 PLN
Upside+74.6%
Quality94/100
Evidence: High Range 96.81 PLN – 279.15 PLN

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Voxel S.A (VOX) currently trades at 115.60 PLN, while our model-based Fair Value estimate is 201.85 PLN — implying the stock looks roughly 74.6% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Voxel S.A. provides medical services in Poland. The company offers imaging diagnostics services, including reimbursed, commercial, and private patient examinations; teleradiology services; and clinical/pharmaceutical trials. It is also involved in the sale of radiopharmaceuticals, and the leasing of land. Voxel S.A. was incorporated in 2005 and is headquartered in Kraków, Poland.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -96% Danaher Corporation (DHR) -52% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -66% Lonza Group (LZAGY) -59% Agilent Technologies, Inc (A) -54%

Frequently asked questions

Is Voxel S.A (VOX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 201.85 PLN versus a price of 115.60 PLN — about +75% (undervalued). Model-based estimate, not financial advice.
What is the fair value of VOX?
Our 21-model fair value for Voxel S.A is 201.85 PLN (as of Jun 24, 2026), built from audited fundamentals. The current price is 115.60 PLN.
What is the quality score of VOX?
Voxel S.A has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.